State Street Corp Increases Position in Vaxcyte, Inc. (NASDAQ:PCVX)

State Street Corp raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 1.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,405,743 shares of the company's stock after buying an additional 38,596 shares during the period. State Street Corp owned about 2.73% of Vaxcyte worth $389,174,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Riverview Trust Co acquired a new stake in shares of Vaxcyte in the 3rd quarter worth about $27,000. Fifth Third Bancorp bought a new position in shares of Vaxcyte in the second quarter valued at approximately $35,000. Blue Trust Inc. boosted its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares during the last quarter. J.Safra Asset Management Corp grew its holdings in Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after buying an additional 526 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in Vaxcyte in the 2nd quarter valued at $70,000. 96.78% of the stock is owned by institutional investors.

Insider Activity at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Grant Pickering sold 2,366 shares of the firm's stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $92.25, for a total transaction of $218,263.50. Following the completion of the transaction, the chief executive officer now owns 136,215 shares of the company's stock, valued at $12,565,833.75. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 117,830 shares of company stock worth $12,600,310. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Stock Performance

NASDAQ PCVX traded down $1.63 on Tuesday, hitting $90.43. 896,274 shares of the stock traded hands, compared to its average volume of 905,458. The firm has a market capitalization of $11.27 billion, a price-to-earnings ratio of -20.07 and a beta of 0.94. The business's fifty day moving average is $103.01 and its two-hundred day moving average is $91.26. Vaxcyte, Inc. has a 12 month low of $53.83 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the business posted ($0.91) earnings per share. Analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on PCVX shares. Bank of America upped their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Mizuho boosted their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 10th. Leerink Partners upped their target price on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.